Adverse Drug Reactions Occurring in the Internal Medicine Service at University Hospital in Neiva
##plugins.themes.bootstrap3.article.main##
Objective. To establish the prevalence of adverse drug reactions (ADR) occurring in the internal medicine service at the Hospital Universitario in Neiva. Design. Cross-sectional, descriptive study. Place. Hospital Universitario Hernando Moncaleano Perdomo, Neiva-Colombia. Population. Patients in Internal Medicine service of Hospital Universitario Hernando Moncaleano Perdomo. Method: Data collection with non-participative direct observation, following an active pharmaco surveillance model. Documentary review of medical histories was performed. Results: Of 303 inpatients in the internal medicine service it was obtained 153 patients with ADRs corresponding to 50% of the sample. Their average age was 63 +/- 4,6. ADRs were grouped by systems: 27.4% affected skin, 13.8% affected the gastrointestinal system, followed by the hematologic and cardiac systems. Regarding medicines related to ADRs, they were divided into groups, as follows: antimicrobials by 37,9%, followed by antihypertensives by 13.3%, anticoagulants by 9,8%. The three most frequent drugs were: vancomycin by 6.6%, enalaprilen by 6,6% and tramadol by 5.3%. When classifying ADRs it was found that 63% corresponded to type A and 46,4% to type B. These ADRs represented 71 cases of the total; the most frequent were: rash by 39.4%, pruritus by 14.3% and cough by 11.2% and a Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome (DRESS) case took place. Fourteen severe cases of ADRs were documented which showed bleeding by 35,8%, IRA by 35,8% among others. Drugs related to these ADRs were: warfarin by 14.4% as well as enoxaparin, and vancomycin.
Downloads
##plugins.themes.bootstrap3.article.details##
INCH J, WATSON MC. Patient vesus healthcare professional spontaneous adverse drug reaction reporting. A systematic review. Drugs safe2012; 35 (10): 807-818.
TABORA L, AMARAL B. Drugs induced vasculitis. Adverse drug reaction bulletin. April 2013. 279 (1): 1075-1078.
KAVITHA D. Adverse drug reaction monitoring pharmacovigilance. J Pharm Res Health Care 2010, pag:127–134.
LAZAROU J, POMERANZ BH. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama 1998;pag: 1200–1205.
BECERRIL A. Encuesta de reacciones adversas a medicamentos en pacientes hospitalizados. Martín. Rev Alergia Mex 2011;58(4):179-184.
TRIBINO G. Direct costs and clinical aspects of adverse drug reactions in patients admitted to a level 3 hospital internal medicine ward. Biomedica. 2006; 26: 31-41.
LÓPEZ et al. Adverse drug reactions in internal medicine units at a university hospital: A descriptive pilot study. Colomb Med. 2010; 41: 45-51.
KELLY W. Potential risks and prevention: Part 1. fatal adverse drug events. Am J Health. Sys Pharm 2001, pag:1317–24.
Pharmacovigilance. ensuring the safe use of medicines. WHO Policy Perspectives on Medicines. World Health Organization 2004 . pg 1–5. January 26, 2010.
World Health Organization -WHO- collaborating center for international drug monitoring. The importance of Pharmacovigilance. 2002.
ANNIE P. C. Data-driven Methods to Discover Molecular Determinants of Serious Adverse Drug Events. Clin Pharmacol Ther. 2009 March; pag: 259–268.
OCAMPO JM. Aspectos farmacológicos y reacciones adversas medicamentosas. En: López JH, Cano CA, Gómez JF (eds). Fundamentos de medicina: Geriatría. Bogotá: Corporación para Investigaciones Biológicas; 2006. p. 128-32.
DANZA A. Adverse drug reaction in an internal medicine unit at the University Hospital. Fonte: Rev. médica Urug; 26(3): 138-144, set. 2010.
HAFNER JW, BELKNAP SM. Adverse drug events in emergency department patients. Ann Emerg Med. 2002; 39: 258-67.
LÓPEZ LC, col et. Reacciones adversas a medicamentos en las unidades de medicina interna en un hospital universitario: un estudio piloto descriptivo. Colomb. Med. vol.41 no.1 Cali. 2010
HOWARD PA, ELLERBECK EF. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf 2002;pag:569–76.